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Summary
Background The OVAMA (Outcome Measures for Vascular Malformations) project
determined quality of life (QoL) as a core outcome domain for patients with vas-
cular malformations. In order to measure how current therapeutic strategies alter
QoL in these patients, a patient-reported outcome measurement (PROM) respon-
sive to changes in QoL is required.
Objectives To assess the responsiveness of two widely used generic QoL PROMs,
the Medical Outcomes Study Short Form 36 (SF-36) and Skindex-29, in adult
patients with vascular malformations.
Methods In an international multicentre prospective study, treated and untreated
patients completed the SF-36 and Skindex-29 at baseline and after a follow-up
period of 6–8 weeks. Global rating of change (GRC) scales assessing various
QoL-related outcome domains were additionally completed. Per subscale, respon-
siveness was assessed using two methods: by testing hypotheses on expected cor-
relation strength between change scores of the questionnaires and the GRC
scales, and by calculating the area under the receiver operating characteristics
curve (AUC). The questionnaires were considered responsive if ≥ 75% of the
hypotheses were confirmed or if the AUC was ≥ 07.
Results Eighty-nine participants were recruited in three centres in the Netherlands
and the U.S.A., of whom 67 completed all baseline and follow-up questionnaires.
For all subscales of the SF-36 and Skindex-29, < 75% of the hypotheses were
confirmed and the AUC was < 07.
Conclusions Our findings suggest that the SF-36 and Skindex-29 seemed unrespon-
sive to change in QoL. This suggests that alternative PROMs are needed to mea-
sure – and ultimately improve – QoL in patients with vascular malformations.
What’s already known about this topic?
• Quality of life is often impaired in patients with vascular malformations.
• Quality of life is considered a core outcome domain for evaluating treatment of
vascular malformations.
• To measure the effect of treatment on quality of life, a patient-reported outcome
measure is required that is responsive to changes in quality of life.
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What does this study add?
• This is the first study assessing the responsiveness of quality-of-life measures in
patients with vascular malformations.
• The results seem to indicate that the Medical Outcomes Study Short Form 36 (SF-36)
and Skindex-29 are not responsive to changes in quality of life in patients with vascular
malformations.
What are the clinical implications of this work?
• Medical Outcomes Study Short Form 36 (SF-36) and Skindex-29 are not ideal to
assess the effect on quality of life over time, of treatment strategies for peripheral
vascular malformations.
Vascular malformations are rare congenital vascular anomalies,
which grow proportionally with age, and can be of venous, lym-
phatic, arteriovenous, capillary or combined origin.1 Patients
with peripheral vascular malformations commonly experience
disfigurement, pain, bleeding, impaired mobility, growth distur-
bances and bleeding and thrombotic complications.1–5 Patients
have overall poorer quality of life (QoL) than the general popula-
tion.6 Some lesions can be life-threatening, but most patients seek
treatment to improve aspects of their QoL.
QoL and other patient-reported outcomes (PROs) were
therefore recently included in the core domain set (CDS) for
clinical research in vascular malformations (excluding capil-
lary).3 A CDS is a minimum set of outcome domains that
should be measured when evaluating treatment outcomes in a
certain health condition.7 The CDS results came from an
international consensus project, the Outcome Measures for
Vascular Malformations (OVAMA) project,3,8 which aims at
uniform outcome reporting by determining what and how to
measure.
PROs included in the CDS are ‘appearance’, ‘overall symp-
tom severity’, ‘pain’, ‘satisfaction with treatment outcome’,
‘satisfaction with treatment’ and multiple aspects of QoL,
namely ‘activities of daily living’, ‘mobility’, ‘ability to work/
study’, ‘confidence and self-esteem’ and ‘emotional wellbe-
ing’. The next step of the OVAMA project is to decide how to
measure these core outcome domains. This comprises selecting
or developing outcome measurement instruments measuring
the core domains, in other words, developing a core outcome
measurement set (COMS).7,9
PROs are measured by patient-reported outcome measures
(PROMs). There is currently no consensus on how to measure
QoL and other core PROs in vascular malformations. Conse-
quently, much is unclear about whether and how current
treatment strategies improve QoL in this patient population.
To improve QoL outcome, the ability to determine correctly
the effect of treatment on different aspects of QoL is essential.
This, in turn, requires a measurement instrument that can
detect change in the desired outcome domains over time.10
Identifying such an instrument involves evaluation of the
measurement property ‘responsiveness’. Responsiveness is
defined as ‘the ability of an instrument to detect change over
time in the construct to be measured.’11,12 Responsiveness can
be assessed by comparing change scores of the measurement
instrument and change scores of instruments measuring
change in similar outcome domains.10,12
In adult patients with peripheral vascular malformations, we
assessed the responsiveness of two widely used QoL question-
naires: the Medical Outcomes Study Short Form 36 (SF-36)
and the Skindex-29. We thereby evaluated the suitability of
these questionnaires to assess treatment effect on the core
aspects of QoL in this population, and therefore whether they
should be considered for inclusion in the COMS for vascular
malformations.
Patients and methods
Patients and data collection
Data were collected prospectively from October 2016 to
September 2017 from adult patients (age ≥ 18 years) with
peripheral vascular malformations (capillary, venous, lymphatic,
arteriovenous or combined vascular malformations) visiting the
outpatient clinics of the Amsterdam University Medical Centre
in Amsterdam, Radboud University Medical Centre in Nijmegen
and the Vascular Birthmark Institute in New York. Informed
consent was obtained from all participants.
Data on patient characteristics were extracted from the elec-
tronic patient files, including sex, age at start of treatment,
type of vascular malformations, size (< 5 cm, 5–10 cm, ≥ 10
cm), location (head/neck, trunk, upper extremities, lower
extremities, combined), lesion depth (skin/subcutaneous tis-
sue, muscle, organs/bone) and previous treatments. We regis-
tered whether the patient received conservative treatment
(watchful waiting or with compression stockings) or invasive
treatment (including sclerotherapy, laser therapy and surgery).
Follow-up occurred 6–8 weeks post-treatment, which is cus-
tomary for evaluating the effect of the treatment in these
clinics.
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Outcome measures
Medical Outcomes Study Short Form 36
The SF-36 is a generic QoL questionnaire consisting of an
item measuring health transition and 35 items forming eight
subscales: (i) physical functioning, (ii) social functioning, (iii)
role physical, (iv) role emotional, (v) mental health, (vi) vital-
ity, (vii) bodily pain and (viii) general health.13 Multiple ver-
sions are available; we used the freely available RAND-36.
Scoring was according to the RAND-36 scoring instructions.14
Higher scores indicate a better QoL.
Using all items, a physical health component score (PCS)
and mental health component score (MCS) can be derived.
We computed Z-scores using age- and sex-specific Dutch pop-
ulation normative data.15 For the SF-36 missing items were
handled following the rules of the SF-36 scoring manual. For
a scale with < 50% of missing items, an imputation method is
provided per subscale for the missing items. If a scale has ≥
50% missing items, the scale scores were not calculated.
Skindex-29
The Skindex-29 is a ‘dermatology-specific’ QoL questionnaire,
containing 29 items forming three subscales: (i) symptoms,
(ii) functioning and (iii) emotions.17 It also contains an addi-
tional item measuring adverse events. Questions refer to the
previous 4 weeks. Higher scores indicate worse QoL. For easy
interpretation, we calculated Skindex-29 change scores so that
a positive change score means improvement, and a negative
change score means worsening. Missing items for the Skin-
dex-29 were computed following the Skindex-29 scoring
instructions.18 When ≥ 25% of the items were missing from a
scale, the scale score was not calculated.
Global rating of change scales
At follow-up, patients filled in global rating of change (GRC)
scales, asking about changes in various QoL domains since the
baseline measurement. We formulated seven GRC scales corre-
sponding with the constructs measured by subscales of the SF-
36 and Skindex-29, based on the subjective significance ques-
tionnaire of Osoba (Appendix S1; see Supporting Informa-
tion).19 Patients were asked how much change they had
experienced in: ‘overall health’, ‘pain’, ‘physical condition’,
‘social relationships and activities’, ‘emotional wellbeing’,
‘ability to perform work/study’ and ‘symptom severity’. Ques-
tions were formulated by thoroughly examining individual
items of the SF-36 and Skindex-29 subscales.
Patients also filled in two GRC scales about other core PROs for
vascular malformations not explicitly covered by the SF-36 and
Skindex-29, namely ‘appearance’ and ‘mobility of the affected
body part’. These were based on preliminary results of the CDS
development study.3 No GRC scale for the SF-36 subscale ‘vital-
ity’ was formulated, because it was not considered a core out-
come domain for patients with vascular malformations.3,8
The change was reported on a seven-point Likert scale,
based on previously reported GRC scales and the subjective
significance questionnaire of Osoba.19,20 Response options
included ‘very much worse’, ‘worse’, ‘somewhat worse’, ‘no
change’, ‘somewhat better’, ‘better’ and ‘very much better’.
Differences between the conservative and invasive treatment
groups were assessed using the Mann–Whitney U-test.
Evaluating responsiveness
Responsiveness was assessed using two methods for seven of
the SF-36 subscales (excluding ‘vitality’) and its two compos-
ite scores, and for the three Skindex-29 subscales. The first
method involved the construct approach, by testing predefined
hypotheses on comparison with other outcome measurement
instruments (the GRC scales). Seven hypotheses were formu-
lated per subscale (Table 1). These hypotheses were based on
previous studies assessing responsiveness and methodology
guidelines by COSMIN.10,12,21–28
The first four hypotheses referred to the strength of correla-
tions between change scores of the PROMs, and the GRC scale
scores. For each PROM subscale, correlation strength was cal-
culated with a GRC scale measuring change in a similar con-
struct (hypothesis 1), two GRC scales measuring related but
dissimilar constructs (hypotheses 2 and 3), and one GRC scale
measuring an unrelated construct (hypothesis 4). Two inde-
pendent researchers (M.M.L. and S.E.R.H.) defined these
expected relations beforehand (Table 2) by thoroughly
reviewing the subscales. Disagreement was resolved by con-
sensus (M.M.L. and S.E.R.H.). Correlations between PROM
Table 1 Hypotheses for testing responsiveness
1. High positive correlation between SF-36 or Skindex-29
change scores and the GRC scale measuring a similar construct
2. Moderate positive correlation between SF-36 or Skindex-29
change score and a GRC scale measuring a related, but
dissimilar construct
3. Moderate positive correlation between SF-36 or Skindex-29
change score and a second GRC scale measuring a related, but
dissimilar construct
4. Low positive or negative correlation between SF-36 or
Skindex-29 change score and a GRC scale measuring an
unrelated construct
5. Patients indicating improvement on the associated GRC scale
should have a positive mean change score
6. Patients indicating worsening on the associated GRC scale
should have a negative mean change score
7. The mean change score of patients indicating improvement
should be higher than the mean change score of unchanged
patients, which in turn should be higher than the mean change
score of worsened patients
Per Medical Outcomes Study Short Form 36 (SF-36) and Skin-
dex-29 subscale, these seven hypotheses were tested. If ≥ 75%
of these hypotheses were confirmed for a subscale, the subscale
was considered responsive to change. GRC, global rating of
change.
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change scores and GRC scale scores were assessed by calculat-
ing Spearman’s rank correlation coefficients. Correlation was
interpreted as high (> 05), moderate (03–05) or low
(< 03), based on previous studies and guidelines for assessing
responsiveness.10,12,21–29 The next hypotheses (5, 6, 7) con-
cerned the mean PROM change scores of improved,
unchanged and worsened patients according to the associated
GRC scale, namely the GRC scale measuring a similar con-
struct. These hypotheses therefore use the same data as
the first hypothesis, but add more detailed insight on the
data. A subscale was considered responsive to change if
≥ 75% of the hypotheses were confirmed, as shown in
Table 1.10,12
The second method for assessing responsiveness involved
calculating the area under the receiver operating characteris-
tics curve (AUC). The AUC indicates how good the instru-
ment is at discriminating patients who improved from those
unchanged. The unchanged and improved groups were based
on the associated GRC scale. As it dichotomizes the data, it
is a rougher but more comprehensible method of interpret-
ing the data. An AUC ≥ 07 is considered appropriate.12,30
All data were analysed with SPSS statistics 250 (IBM,
Armonk, NY, U.S.A.).
Results
In total, 109 patients were approached, of whom 89 were
included. Sixty-seven (75%) of the included patients com-
pleted the SF-36 and Skindex-29 at baseline and follow-up,
and also filled in the GRC scales.
Baseline characteristics
The baseline characteristics of all patients who completed
the questionnaires at baseline and follow-up and the GRC
scales are shown in Table 3. Compared with the 89
included patients, the 20 excluded patients had signifi-
cantly fewer patients in the > 10cm size category
(P = 0003). No statistically significant differences in
baseline characteristics were found between patients who
completed both baseline and follow-up questionnaires and
those who did not.
Table 2 Predefined expected correlations between Medical Outcomes Study Short Form 36 (SF-36) and Skindex-29 change scores and global




GRC scale measuring related,
but dissimilar construct #1
(expected moderate correlation)







SF-36 GH Overall health Physical condition Emotional wellbeing Appearance
SF-36 BP Pain Overall health Symptom severity Appearance
SF-36 PF Physical condition Overall health Pain Appearance
SF-36 SF Social relationships
and social activities








SF-36 RP Ability to perform work,
study or school-related
activities
Overall health Physical condition Appearance
SF-36 RE Ability to perform work,
study or school-related
activities
Overall health Emotional wellbeing Mobility of affected
body part
SF-36 PCS Physical condition Overall health Pain Appearance




SF-36 sum Overall health Physical condition Symptom severity Appearance
Skindex S Symptom severity Overall health Pain Appearance
Skindex F Social relationships
and social activities
Overall health Ability to perform work, study
or school-related activities
Appearance




Skindex sum Overall health Emotional wellbeing Symptom severity Appearance
Per SF-36 and Skindex-29 subscale, a GRC scale measuring change in a similar construct was determined, with which a high correlation was
expected. Moderate correlation was expected with GRC scales measuring change in a related, but dissimilar construct (two defined per sub-
scale). Low correlation was expected with a GRC scale measuring change in an unrelated construct. Correlation was interpreted as high
(> 05), moderate (03–05) or low (< 03). GH, general health; BP, bodily pain; PF, physical function; SF, social function; MH, mental
health; RP, role physical; RE, role emotional; PCS, physical health component score; MCS, mental health component score; S, symptoms; F,
functioning; E, emotions.
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Descriptive data of Medical Outcomes Study Short Form
36 and Skindex-29
Table S1 (see Supporting Information) shows descriptive data
of SF-36 and Skindex-29 scores at baseline and follow-up.
This includes patients who filled in the questionnaires at both
baseline and follow-up. For all SF-36 and Skindex-29 sub-
scales, no significant change was observed between baseline
and follow-up. No significant differences were found between
the conservative and invasive management groups in baseline
scores or change scores. At the baseline measurement, one
patient had missing data on the SF-36 ‘role physical’ subscale,
and one different patient had missing data on the SF-36 ‘role
emotional’ subscale.
Global rating of change scale responses
An overview of the results of the GRC scales is shown in
Table S2 (see Supporting Information). Patients who received
an invasive treatment indicated more improvement than the
conservative group in all GRC scale domains, of which the fol-
lowing were significant by Mann–Whitney U-test: overall
health (P = 001), pain (P = 004), emotional wellbeing (P =
002), ability to perform work/study (P = 002), symptom
severity (P = 0003), appearance (P = 0008) and mobility of
the affected body part (P = 0005).
Correlation between Medical Outcomes Study Short Form
36 and Skindex-29 score changes and global rating of
change scale scores
An overview of the Spearman’s rank correlation coefficients
between the SF-36 and Skindex-29 scales and all GRC scales is
presented in Table S3 (see Supporting Information). No SF-36
or Skindex-29 sum or subscale had high correlation with the
GRC scale for which high correlation was expected (GRC scale
measuring a similar construct). The Skindex-29 ‘symptoms’
subscale came closest, with a moderate correlation (034) with
its predefined GRC scale measuring a similar construct (symp-
tom severity). No SF-36 or Skindex-29 scale reached moderate
correlation with GRC scales for which moderate correlation
was expected (GRC scales measuring related but dissimilar
constructs). All SF-36 or Skindex-29 scales had low correlation
with the GRC scales for which a low correlation was expected
(GRC measuring an unrelated construct).
Responsiveness: hypothesis testing and area under the
receiver operating characteristics curve
Table 4 shows the results of hypothesis testing and the AUC
values for each subscale. For no sum or subscale were ≥ 75%
of hypotheses correct. In addition, for no sum or subscale was
the AUC ≥ 07. Consequently, all scales of both the SF-36 and
Skindex-29 were considered not responsive to change.
Table S4 (see Supporting Information) shows the exact values
on which the hypotheses were confirmed or rejected.
Correlation between Medical Outcomes Study Short Form
36 change scores and Skindex-29 change scores
An overview of Spearman’s rank correlation coefficients
between SF-36 change scores and Skindex-29 change scores is
presented in Table S5 (see Supporting Information). We chose
Table 3 Baseline characteristics of the 67 patients who completed the
questionnaires at baseline and follow-up, and the global rating of
change scales
Age at baseline (years), median (IQR) 39 (26–50)




Venous, capillary 6 (9)
Lymphatic 5 (7)
Venous, lymphatic 5 (7)
Venous, lymphatic, capillary 3 (4)
Arteriovenous, capillary 1 (1)
Capillary 1 (1)
Not specified 1 (1)
Localization
Lower extremity 21 (31)
Head/neck 19 (28)
Trunk, lower extremity 9 (13)
Trunk 8 (12)
Upper extremity 6 (9)
Head/neck, trunk, upper extremity 2 (3)
Head/neck, trunk, upper extremity,
lower extremity
1 (1)
Trunk, upper extremity, lower extremity 1 (1)
Size
< 5 cm 20 (30)
5–10 cm 12 (18)
> 10 cm 35 (52)
Depth/extension




No prior treatment 22 (33)
Surgery 11 (16)
Elastic stockings 7 (10)
Embolization 3 (4)
Laser therapy 2 (3)
Sclerotherapy 2 (3)
Anticoagulants 1 (1)
A combination of the above 19 (28)
Treatment during study period
Conservative 42 (63)
Expectant management 34 (51)
Elastic stockings 7 (10)
Invasive 25 (37)
Sclerotherapy 15 (22)




Sclerotherapy, laser therapy 1 (1)
Data are presented as n (%) except for age.
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to calculate these correlations with the Spearman’s rank test,
as the change scores were not normally distributed. The only
moderate correlation was between the SF-36 ‘social function-
ing’ subscale and the Skindex-29 ‘functioning’ subscale
(033). All other correlations were low.
Discussion
These data suggest that all subscales of both the SF-36 and
Skindex-29 were unresponsive to change in QoL in this study
population of patients with peripheral vascular malformations.
Our study therefore implies that these PROMs are not ideal to
assess the effect on QoL over time of treatment strategies for
peripheral vascular malformations. As of yet, they seem unreli-
able for inclusion in the COMS for peripheral vascular malfor-
mations.
To our knowledge, this is the first study assessing the
responsiveness of QoL questionnaires in patients with vascular
malformations. In a systematic review on measurement instru-
ments used in patients with vascular malformations,31 we
found no studies assessing responsiveness in this population
or similar populations. Very little was found on the assessment
of responsiveness of the SF-36 and Skindex-29 in other patient
populations, and in the studies that we found, mostly out-
dated methods were used.32–36
Our hypotheses for testing responsiveness were formulated
according to the COSMIN methodology and previous studies
assessing responsiveness. The hypotheses for determining
responsiveness are somewhat subjective; however, as none of
the numerous hypotheses were confirmed, the results seem
indisputable.
Although GRC scales are viewed as the best single measure
of the importance of change from the patient’s perspective,37
it is difficult to establish evidence that this is the correct
assessment of change. It is impossible to determine the
responsiveness to change of GRC scales, as they directly assess
change with a single measurement. What supports the accu-
racy of the GRC scales in this study is that patients treated
invasively indicated significantly more improvement in almost
all GRC scales than patients treated conservatively. Also, the
low correlation coefficients between SF-36 and Skindex-29
scales measuring similar or related constructs support our con-
clusion that these questionnaires may not correctly detect
change in the constructs they aim to measure.
Symptoms of vascular malformations are known to vary
according to type, size and location. This, combined with the
rarity of the disease, makes a heterogeneous study population
unavoidable. The responsiveness to change of these question-
naires might differ for certain subgroups. However, our objec-
tive is to find a PROM suitable for all peripheral vascular
Table 4 Testing results of the hypotheses for evaluation of responsiveness. Exact definitions of the hypotheses are shown in Table 2. Exact values
are presented in Table S4 (see Supporting Information)





























SF-36 GH Low Low Low Low Negative Positive No 14% < 07 No
SF-36 BP Low Low Low Low Positive Positive No 29% < 07 No
SF-36 PF Low Low Low Low Positive Negative Yes 57% < 07 No
SF-36 SF Low Low Low Low Negative Negative No 29% < 07 No
SF-36 MH Low Low Low Low Positive Negative Yes 57% < 07 No
SF-36 RP Low Low Low Low Positive Positive No 29% < 07 No
SF-36 RE Low Low Low Low Positive Positive No 29% < 07 No
SF-36 PCS Low Low Low Low Positive Positive No 29% < 07 No
SF-36 MCS Low Low Low Low Positive Negative Yes 57% < 07 No
SF-36 sum Low Low Low Low Positive Negative Yes 57% < 07 No
Skindex S Moderate Low Low Low Positive Negative Yes 57% < 07 No
Skindex F Low Low Low Low Negative Positive No 14% < 07 No
Skindex E Low Low Low Low Positive Positive No 29% < 07 No
Skindex sum Low Low Low Low Positive Positive No 29% < 07 No
Confirmed hypotheses are shown in bold. A subscale was considered responsive to change if ≥ 75% of the hypotheses were confirmed. GRC,
global rating of change; AUC, area under the receiver operating characteristics curve; GH, general health; BP, bodily pain; PF, physical func-
tion; SF, social function; MH, mental health; RP, role physical; RE, role emotional; PCS, physical health component score; MCS, mental health
component score; S, symptoms; F, functioning; E, emotions. aSimilar: correlation strength with the GRC scale measuring a similar construct
as defined in Table 1. Related #1: correlation strength with the first GRC scale measuring a related, but dissimilar construct as defined in
Table 1. Related #2: correlation strength with the second GRC scale measuring a related, but dissimilar construct as defined in Table 1.
Unrelated: correlation strength with the GRC scale measuring an unrelated construct as defined in Table 1. Correlation was interpreted as
high (> 05), moderate (03–05) or low (< 03). bThe mean change score of the patients indicating improvement on the associated GRC
scale. cThe mean change score of the patients indicating worsening on the associated GRC scale.
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malformations. The COMS for vascular malformations should
include outcome measurements responsive to change for all
patients with peripheral vascular malformations.
A sample size of > 50 is considered adequate for studies on
responsiveness,38 although in another guideline, sample size
standards were explicitly removed.21 Either way, our sample is
more than sufficient, especially considering that a study popu-
lation of 67 is exceptionally high for studies on this rare dis-
ease. If a much larger study population is needed in order to
observe differences, this would mean that the questionnaire
might not be a feasible option to measure treatment effect in
this patient population.
A possible explanation for the difference in size between
the included and excluded patients might be that patients with
larger vascular malformations are more willing to fill in the
questionnaires, as their life might be impacted more by the
disease. Future research with an adequate QoL measurement
instrument must uncover the relationship between malforma-
tion size and QoL.
Even though a period of 6–8 weeks post-treatment is stan-
dard for evaluating treatment effect, a longer follow-up period
might be necessary to measure some QoL aspects. This may
especially be the case for the outcome domains ‘social rela-
tionships and social activities’ and ‘ability to perform work/
school/study’. On the contrary, the same constructs measured
by the GRC scales were often considered improved by the par-
ticipating patients. In seven of the outcome domains there
were more than 10 patients indicating improvement. More-
over, a large group of patients underwent invasive treatment;
change could be expected in this group. Although significant
differences were found between the invasive group and the
conservatively managed group in seven of nine GRC scales,
there were no significant differences in the corresponding SF-
36 and Skindex-29 change scores.
Interpretability, mostly determined by the minimal impor-
tant change (MIC) and smallest detectable change (SDC) of
the questionnaire, is an important characteristic of a PROM,10
defined as ‘the degree to which one can assign qualitative
meaning to an instrument’s quantitative scores or change in
scores.’12 Only one subscale satisfied the criteria for calculat-
ing the MIC and SDC (≥ 03 correlation with its anchor, the
associated GRC scale): the Skindex-29 ‘symptoms’ scale. Using
different methods, we found MICs of 5–8 points, next to a
very large SDC (37 points). However, interpretability is only
meaningful if the measurement instrument shows agreeable
responsiveness. In other words, in order to calculate which
‘changes’ in questionnaire scores are clinically important,
there have to be actual measurable ‘changes’ in the question-
naire scores, which we did not find in this study. Thus, the
MIC values are not reliable and would be unfitting to show in
the results section. However, in light of the large measure-
ment error it suggests that, if this scale were responsive to
change, it would probably not be able to detect meaningful
change on an individual level.
We found similar large measurement errors for the other
subscales, which possibly is the reason why these PROMs
showed insufficient responsiveness. It is possible that in larger
study populations, responsiveness might improve because of a
smaller measurement error. However, clinical research on vas-
cular malformations mostly involves smaller patient groups, so
a PROM with smaller measurement error is needed. Causes of
the large measurement errors might be that the PROMs were
developed for use in larger populations, or that the items and
response options are not appropriate for this population.
Another reason for low responsiveness might be that the sub-
scales of the SF-36 and Skindex-29 measure multiple con-
structs of interest, averaging out possible change in one of
these constructs. In addition, the scales might contain irrele-
vant questions for patients with vascular malformations, mask-
ing change in the items of interest.
If we want to improve the most important outcomes from
the perspective of patients with vascular malformations, we
need a PROM that can detect changes in the core PROs (in-
cluding QoL) over time to evaluate effects of treatment strate-
gies. The next step in improving assessment of QoL in
patients with vascular malformations is therefore identifying
PROMs that are capable of detecting change in the core PROs
over time. Other existing PROMs may be explored, or a new
disease-specific PROM will have to be developed. The solution
might be using PROMs that have smaller measurement error,
have good content validity and measure the core PROs for vas-
cular malformations more ‘unidimensionally’.
New methodologies such as item response theory and com-
puter adaptive tests enable tailoring of questionnaires to the
individual, which improves precision and accuracy.39 Especially
in a heterogeneous patient population such as this, these might
have better measurement properties. We plan on exploring the
measurement properties of the unidimensional Patient-Reported
Outcomes Measurement Information System (PROMIS) item
banks, which were developed with item response theory and
can be administered as computer adaptive tests.40 Because not
all outcome domains from the CDS can potentially be covered
by PROMIS scales, we also plan on developing a disease-specific
questionnaire, with a focus on appearance and disease-specific
symptoms for vascular malformations.
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